Cenexi regulatory delays
Unannounced ANSM inspection at Fontenay caused production loss and corrective measures, pushing EBITDA breakeven to Q3 FY26. Further regulatory actions could delay recovery.
high · management_commentaryGland Pharma Limited — Q3 FY25
Gland Pharma's Q3 FY25 consolidated revenue was INR 1,384 crore, with EBITDA margin improving 100 bps YoY to 26%.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Volume recovery in US base business
Base business revenue declined 8% YoY due to volume degrowth in key products like Enoxaparin. Recovery depends on timing of shipments and new product ramp-up.
medium · data_observationSaudi tender revenue deferral
The Saudi tender shipment was pushed out by a quarter, impacting Q3 revenue. Further delays could affect near-term ROW growth.
medium · analyst_questionChinese competition and tariff uncertainty
Chinese players control 50-60% of Heparin API supply. While US tariffs may benefit Gland, raw material dependence on China remains a risk.
medium · analyst_question